Multiple sclerosis
Merck KGaA launches campaign to educate doctors on rare MS type, challenging Sanofi
Merck KGaA is gearing up for a significant milestone in the development of its multiple sclerosis (MS) drug candidate. As ...
Rocheās BTK inhibitor shows potential to cross blood-brain barrier in MS trial
Roche is touting its multiple sclerosis (MS) drug as a potential game-changer in the field, asserting that it has achieved ...
Rocheās Ocrevus shows similar efficacy and safety in subcutaneous and intravenous forms
Roche’s innovative subcutaneous adaptation of its highly-regarded multiple sclerosis (MS) medication, Ocrevus, has achieved a significant breakthrough in a pivotal ...
Immunicās MS drug shows positive biomarker results in phase 2 trial, boosting investor confidence
Immunic Therapeutics’ strategic decision to refocus its efforts earlier this year appears to be yielding positive results, drawing favorable reactions ...
Teva Gains Trial Postponement for Unique Appeal Strategy in Copaxone Case Against US Government
After an enduring three-year legal battle against allegations by the US government, Teva Pharmaceuticals has managed to secure a delay ...
TG Therapeutics Partners with Neuraxpharm to Launch Game-Changing Multiple Sclerosis Antibody Briumvi Worldwide
After gaining approval for Briumvi in the US eight months ago, TG Therapeutics is now set to introduce its multiple ...
Sandoz’s Biosimilar Natalizumab Receives Positive CHMP Opinion for Multiple Sclerosis Treatment
Source – Novartis On July 24, 2023 Sandoz announced a significant milestone. The Committee for Medicinal Products for Human Use ...
Promising Phase III Results: OCREVUS (Ocrelizumab) Subcutaneous Injection Offers Convenient and Efficient Treatment for Multiple Sclerosis
Source – Roche On 13 July Roche announced positive results from the Phase III OCARINA II trial, which investigated the ...
